News

Neuropharm seeks collaborator for autism project

Country
United Kingdom

Neuropharm Group Plc said that it seeking a collaborator to help carry out a second Phase 3 study of its treatment for autism, NPL-2008. In the meantime it has put a hold on further outlays for the project, its lead compound.

Shake-up at Affitech continues

Country
Denmark

The new management of Affitech A/S has made two senior appointments, closed two offices and sharpened its therapeutic focus to concentrate on the development of antibodies to cell-surface targets. It has also revised upward its loss for 2009.

Silence Therapeutics in reverse takeover talks

Country
United Kingdom

Silence Therapeutics Plc, which is working in the field of ribonucleic acid interference (RNAi), said that it is in talks that could lead to a reverse takeover of the company. Trading in the company’s London-listed shares has been suspended.

Pharming pulls a transgenic rabbit out of a hat

Country
Netherlands

The Pharming Group NV has metaphorically pulled a transgenic rabbit out of a hat by submitting an expanded marketing authorisation application to the European Medicines Agency for Rhucin, a treatment for hereditary angioedema, and by persuading 70% of its convertible bondholders to forego receiving €50,000 per bond in three years and instead accept €7,500 plus shares now.

Four new drugs get positive EMEA opinions

Country
United Kingdom

The European Medicines Agency is recommending that four new drugs be allowed onto the market in Europe including a new therapy from Sanofi-Aventis for the treatment of atrial fibrillation.

Novartis and GSK vaccines for swine flu get go ahead from EMEA

Country
United Kingdom

The European Medicines Agency has recommended that two vaccines for influenza A (H1N1), known as swine flu, be granted a European Union-wide marketing authorisation. The vaccines are Focetria from Novartis and Pandemrix from GlaxoSmithKline.